Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selumetinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 0.79 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 0.79 |
| ▸ | SMC2 | O95347 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.79 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.79 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.79 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.79 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | BRAF | P15056 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selumetinib SCHEMBL30487260 | 0.95 | MAP2K1 (0.88) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487255 | 0.94 | MAP2K1 (0.89) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL31162756 | 0.94 | MAP2K1 (0.74) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487256 | 0.89 | MAP2K1 (0.82) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29353582 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29555068 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL155456 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546029 | 0.87 | MAP2K1 (0.91) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546010 | 0.87 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL21501424 | 0.87 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3712133-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX INC (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-12116348-B2 | Substituted benzimidazole compound and composition comprising same | SHENZHEN TARGETRX, INC. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116348-B2 | Substituted benzimidazole compound and composition comprising same | REN, BRAF, CDK4 | MAP2K1 12/4885MAP2K2 33/4885SMC2 3970/4885 |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | REN, BRAF, CDK4 | MAP2K1 12/4885MAP2K2 33/4885SMC2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.